Kelly Odum
Family · Spring Hill, TNNPI 1841572922
Payments from drug & device makers
Across 240 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$707
- Pfizer$524
- Astellas Pharma US Inc$328
- Lilly USA, LLC$201
- AstraZeneca$197
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,02298%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $1,021 |
| Novo Nordisk | 39 | $707 |
| Pfizer | 32 | $524 |
| Astellas Pharma US Inc | 14 | $328 |
| Lilly USA, LLC | 12 | $201 |
| AstraZeneca | 14 | $197 |
| Boehringer Ingelheim | 13 | $196 |
| GSK | 9 | $157 |
| Biohaven Pharmaceuticals, Inc. | 8 | $121 |
| Exact Sciences | 6 | $103 |
| Abbott | 5 | $102 |
| Merck | 5 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Amgen | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 1 | $32 |
| Eisai Inc. | 2 | $31 |
| Johnson & Johnson | 1 | $25 |
| Bayer | 1 | $25 |
| Impel Pharmaceuticals Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $12 |
How this compares
$4,122 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 76 | $89,805 |
| OzempicSemaglutide | 34 | $48,435 |
| MounjaroTirzepatide | 35 | $42,109 |
| XareltoRivaroxaban | 25 | $30,808 |
| RybelsusSemaglutide | 14 | $27,779 |
| EliquisApixaban | 23 | $24,039 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $19,247 |
| MyrbetriqMirabegron | 11 | $11,082 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $10,204 |
| SynthroidLevothyroxine Sodium | 41 | $3,626 |
| Atorvastatin Calcium | 277 | $2,997 |
| Rosuvastatin Calcium | 169 | $2,827 |
| Omeprazole | 186 | $2,821 |
| Nebivolol Hcl | 19 | $2,238 |
| Losartan Potassium | 183 | $2,156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $196 | $89,80576 claims |
| Novo NordiskOzempic, Rybelsus | $707 | $76,21448 claims |
| Lilly USA, LLCMounjaro | $201 | $42,10935 claims |
| Johnson & JohnsonXarelto | $25 | $30,80825 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $157 | $29,45135 claims |
| PfizerEliquis | $524 | $24,03923 claims |
| Astellas Pharma US IncMyrbetriq | $328 | $11,08211 claims |
| AbbVieSynthroid | $1,021 | $3,62641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.
Other family in Spring Hill
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.